Okay, let's tackle this question about Omalizumab's administration route in asthma. First, I need to recall what Omalizumab is. It's a monoclonal antibody, right? Targeting IgE, used for allergic asthma. So, the question is about how it's administered.

The core concept here is the pharmacokinetics of Omalizumab. Since it's a monoclonal antibody, it's a large molecule. Large molecules can't be given orally because they get digested, so they need parenteral routes. Common routes for such drugs are subcutaneous or intravenous. But Omalizumab specifically—I remember it's given subcutaneously. Maybe in a clinical setting, patients get it as an injection under the skin, perhaps in the abdomen or thigh.

Now, the options aren't listed, but the correct answer is likely subcutaneous. Let me think about the other options. If the options included oral, intramuscular, or intravenous, those would be incorrect. Oral is out because of digestion. Intravenous might be for some biologics, but Omalizumab is subcutaneous. Intramuscular is less common for monoclonal antibodies due to absorption issues.

Why is subcutaneous the right choice? Because it allows for slower absorption into the bloodstream, maintaining a steady level. Subcutaneous injection is also more convenient for patients compared to IV infusions, which require longer time in a clinic. Omalizumab is typically administered every 2-4 weeks, depending on IgE levels and body weight.

Clinical pearl: Remember that biologics like Omalizumab, mepolizumab, reslizumab are often given via subcutaneous or IV routes. Omalizumab specifically is subcutaneous. A high-yield fact here is that subcutaneous administration is standard for Omalizumab in allergic asthma, and students should not confuse it with IV administration used for other biologics like mepolizumab.

Wait, the user provided the correct answer but didn't list the options. So, in the explanation, I need to address each wrong option. Since the options aren't given, I'll have to assume typical distractors. Let's say the options are oral, IV, subcutaneous, and intramuscular. Then, explain why each is wrong except subcutaneous.

So, putting it all together: the core concept is the route for monoclonal antibodies. Correct answer is subcutaneous. Other options are incorrect because oral is ineffective, IV is not standard, intramuscular is not used for this drug. Clinical pearl: Omalizumab is subcutaneous, every 2-4 weeks.

**Core Concept**
Omalizumab is a monoclonal antibody targeting IgE, used in moderate-to-severe allergic asthma. Its route of administration is determined by its pharmacokinetic profile as a large biologic molecule requiring parenteral delivery for bioavailability.

**Why the Correct Answer is Right**
Omalizumab is administered **subcutaneously** because it is a large, protein-based drug that cannot be absorbed orally. Subcutaneous injection allows slow absorption into systemic circulation, ensuring sustained therapeutic levels. It is typically injected in the abdomen, thigh, or upper arm, with dosing intervals of

✓ Correct Answer: A. Subcutaneous